"PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation." Gastroenterology
USP - Peptide Standards: Discusses challenges in peptide regulation and impurity assessment
They are coming off the Category 2 restricted list effective April 23, 2026, with PCAC review of their compounding eligibility scheduled for July 23-24, 2026
BPC-157 has been proposed as a potential treatment of physiologically based illnesses that disproportionately affect certain patient populations, such as the COVID-19 illness, as it improves vascular integrity and immune response, reduces the pro-inflammatory profile, has an anti-inflammatory effect, and reduces the lethality of critical COVID-19 illnesses [3]
Step 1: Clarify the clinical goal Good prescribing starts with the actual problem
Methylcobalamin, while slightly less stable, remains safe and effective when handled properly in a clinical setting